ZDHHC4 and melanoma: Based on this approach, and considering the fact that the B16F10 melanoma model is resistant to anti-PD-1 alone [20] and that we observed a deficiency in potent anticancer DC1s in this model, we combined FLT3L-BMDC injections to the anti-PD-1, to restore, at least partially, a potent DC1 population in the lung at the time of PD-1/PD-L1 axis blockade.